CELU
CelularityยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CELU Profile
Celularity Inc.
A clinical stage biopharmaceutical company that develops placenta-derived allogeneic cell therapies for cancer, infectious and degenerative diseases
Biological Technology
08/29/2016
08/08/2019
NASDAQ Stock Exchange
123
12-31
Common stock
170 Park Ave, Florham Park, NJ 07932
--
Celularity Inc. was incorporated under the laws of the State of Delaware on August 29, 2016. Cellarity is a clinical-stage biotechnology company that is leading the next development direction of cell medicine by developing off-the-shelf placenta-derived allogeneic T cells, utilizing chimeric antigen receptor cells, natural killer cells (" NK ") cells and mesenchymal adhesion stromal cells (" ASCs ") for cancer, infectious and degenerative diseases. Cellarity believes that by leveraging the unique biology and ready availability of the placenta, it will be able to develop therapeutic solutions to meet the significant global demand for effective, accessible and affordable treatments.
